S&P 500 rises as health care, tech gain to overshadow Fed independence concerns
Investing.com - Dianthus Therapeutics (NASDAQ:DNTH), with a market capitalization of $760 million and showing strong momentum with a 14% gain last week, maintains its Overweight rating at Cantor Fitzgerald ahead of upcoming Phase 2 clinical trial results for its generalized myasthenia gravis (gMG) treatment. According to InvestingPro data, analyst price targets range from $40 to $92, suggesting significant upside potential.
Cantor Fitzgerald reiterated its Overweight rating on Dianthus, naming it a "Top Pick" in anticipation of September 2025 Phase 2 MaGic trial data for claseprubart (DNTH103), the company’s antibody inhibitor targeting the classical complement pathway. InvestingPro analysis shows the company maintains a strong financial position with a healthy current ratio of 13.12 and more cash than debt on its balance sheet.
The firm notes that gMG represents a multi-billion dollar commercial opportunity with U.S. patient estimates ranging from 36,000 to over 120,000, creating space for multiple successful treatments in the market.
Cantor Fitzgerald calculates that each 1,000 patients could represent $275 million to $540 million in annual sales, based on pricing comparisons with existing treatments VYVGART and ULTOMIRIS.
The research firm highlights claseprubart’s potential competitive advantages, including a twice-weekly at-home autoinjector administration versus in-clinic intravenous or daily subcutaneous options, along with an enhanced safety profile without Black Box warnings or Risk Evaluation and Mitigation Strategy (REMS) requirements.
In other recent news, Dianthus Therapeutics has been in the spotlight with several updates. Guggenheim reiterated its Buy rating on the company and raised the stock price target from $84.00 to $92.00 ahead of the anticipated clinical trial results for its DNTH103 treatment in generalized myasthenia gravis, expected in September 2025. Stifel also maintained a Buy rating with a $52.00 price target, noting the significance of the upcoming Phase II data as the first clinical readout for the company in this autoimmune condition. William Blair initiated coverage on Dianthus Therapeutics with an Outperform rating, assigning a fair value of $47.57 per share, marking the company’s 13th Buy rating.
In other developments, The Oncology Institute announced the appointment of Anne McGeorge as the new Chairman of the Board, effective August 12, 2025. McGeorge, who joined the board in 2021 and serves as Chair of the Audit Committee, brings extensive healthcare financial experience to the role. Her previous role included launching and leading Grant Thornton LLP’s Global Health (NSE:GLOH) Care and Life Sciences Practice. These recent developments highlight significant strategic and clinical advancements for both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.